Adicet Bio to Participate in the Canaccord Genuity 2021 Horizons in Oncology Virtual Conference
MENLO PARK, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer, will be participating in a panel discussion at the Canaccord Genuity 2021 Horizons in Oncology Virtual Conference.
| Details of the event are as follows: | |
| Panel: | Gamma Delta CART-Cells, and “Squeezed” T-cells |
| Date: | Thursday, April 15, 2021 |
| Time: | 1:00 – 1:55 PM ET |
| Format: | Panel moderated by John Newman, Ph.D., Managing Director, Biotechnology Analyst |
About Adicet Bio, Inc.
Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at
Adicet Bio., Inc.
Investor and Media Contacts
Anne Bowdidge
Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
